Drug
Imetelstat
Imetelstat: highest development phase Phase 3, developed by Geron Corporation. 17 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Geron Corporation
Trials
| Drug | Phase | Indication |
|---|---|---|
| Imetelstat NCT04576156 | Phase 3 | Myelofibrosis |
| Imetelstat Sodium NCT02598661 | Phase 2/3 | Myelodysplastic Syndromes |
| Imetelstat sodium NCT05583552 | Phase 2 | Myelodysplastic Syndromes |
| Imetelstat NCT01243073 | Phase 2 | Essential Thrombocythemia |
| Imetelstat (7.5 mg/kg) NCT01242930 | Phase 2 | Multiple Myeloma |
| imetelstat NCT01137968 | Phase 2 | Non-small Cell Lung Cancer |
| Imetelstat sodium NCT01256762 | Phase 2 | Locally Recurrent or Metastatic Breast Cancer |
| Imetelstat NCT01731951 | Phase 2 | Primary Myelofibrosis |
| Imetelstat NCT07549451 | Phase 2 | Phase II |
| Imetelstat Sodium (GRN163L) NCT00310895 | Phase 1 | Solid Tumor Malignancies |
| Imetelstat Sodium (GRN163L) NCT00510445 | Phase 1 | Lung Cancer |
| Imetelstat sodium NCT05371964 | Phase 1 | Myelofibrosis |
| Imetelstat Sodium (GRN163L) NCT00718601 | Phase 1 | Multiple Myeloma |
| imetelstat NCT07909733 | Phase 1 | High-risk Myeloid Malignancy |
| Imetelstat NCT01916187 | Phase 1 | Neuroblastoma |
| Imetelstat NCT07320235 | Phase 1 | Relapsed Acute Myeloid Leukemia |
| Imetelstat Sodium (GRN163L) NCT00594126 | Phase 1 | Multiple Myeloma |
Latest
No recent events.
Follow Imetelstat on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.